Imara

About:

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Website: http://www.imaratx.com

Twitter/X: imarainc

Top Investors: Pfizer, Alexandria Venture Investments, RA Capital Management, OrbiMed, New Enterprise Associates

Description:

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types.